{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Bezlotoxumab: A New Drug for the Toxic Effects of Clostridium Difficile
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Description
Accreditation Statement:
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Purpose of Activity
To provide information about the new drug bezlotoxumab.Learning Objectives
After completing this continuing education activity you will be able to:
- Describe Clostridium difficile (C. diff) infection and the challenges of its treatment.
- Explain the mechanism of action, dosage and administration, contraindications, and side effects of bezlotoxumab.
Disclosures
The authors, faculty, and staff have no relevant financial relationship with any ineligible organizations regarding this educational activity.
Price:
$10.00
Credits:
- ACPE 1.0 CH
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0431-0000-22-013-H04-P
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Professions:
Pharmacist
Test Code: GN0717BPharm
Published: February
Expires: 9/12/2025
Sources:
Allied Health Collection
Required Passing Score: 9/12 (75%)
Categories:
Pharmacology
Specialties:
Infectious Diseases,
Pharmocotherapy
Topics:
Infection